Sieminski Mariusz, Reimus Michalina, Kałas Maria, Stępniewska Ewelina
Department of Emergency Medicine, Medical University of Gdańsk, 80-214 Gdańsk, Poland.
Emergency Department, University Clinical Center, 80-952 Gdańsk, Poland.
Antioxidants (Basel). 2024 Dec 28;14(1):25. doi: 10.3390/antiox14010025.
Traumatic brain injury (TBI) is a disease resulting from external physical forces acting against the head, leading to transient or chronic damage to brain tissue. Primary brain injury is an immediate and, therefore, rather irreversible effect of trauma, while secondary brain injury results from a complex cascade of pathological processes, among which oxidative stress and neuroinflammation are the most prominent. As TBI is a significant cause of mortality and chronic disability, with high social costs all over the world, any form of therapy that may mitigate trauma-evoked brain damage is desirable. Melatonin, a sleep-wake-cycle-regulating neurohormone, exerts strong antioxidant and anti-inflammatory effects and is well tolerated when used as a drug. Due to these properties, it is very reasonable to consider melatonin as a potential therapeutic molecule for TBI treatment. This review summarizes data from in vitro studies, animal models, and clinical trials that focus on the usage of melatonin in TBI.
创伤性脑损伤（TBI）是一种由作用于头部的外部物理力量导致的疾病，会引起脑组织的短暂或慢性损伤。原发性脑损伤是创伤的直接且因此相当不可逆的效应，而继发性脑损伤则由一系列复杂的病理过程引起，其中氧化应激和神经炎症最为突出。由于TBI是全球范围内导致死亡和慢性残疾的重要原因，且社会成本高昂，任何可能减轻创伤引起的脑损伤的治疗方法都是可取的。褪黑素是一种调节睡眠-觉醒周期的神经激素，具有强大的抗氧化和抗炎作用，用作药物时耐受性良好。由于这些特性，将褪黑素视为TBI治疗的潜在治疗分子是非常合理的。这篇综述总结了来自体外研究、动物模型和临床试验的数据，这些研究聚焦于褪黑素在TBI中的应用。
